Antibodydrug conjugates a perfect synergy

Expert Opinion on Biological Therapy

Volumn 12, Issue 9, 2012, Pages 1191-1206

  Adair, John R ^a   Howard, Philip W ^b   Hartley, John A ^b,c   Williams, David G ^b   Chester, Kerry A ^c  

^a ST JOHN S COLLEGE   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ADC; Antibody; Antibodydrug conjugate; Cancer; Chemotherapy; Clinical trial; Oncology

Indexed keywords

ALPHA AMANITIN; ANTIBODY; BRENTUXIMAB VEDOTIN; CALICHEAMICIN; DUOCARMYCIN A; DUOCARMYCIN DERIVATIVE; FC RECEPTOR; MACROGOL; MAYTANSINE; IMMUNOTOXIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BINDING AFFINITY; CHEMICAL BOND; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TARGETING; IN VIVO STUDY; LIVER TOXICITY; REVIEW; ANIMAL; BIOTECHNOLOGY; HUMAN; IMMUNOLOGY; NEOPLASM; TREATMENT OUTCOME;

ANIMALS; BIOTECHNOLOGY; HUMANS; IMMUNOTOXINS; NEOPLASMS; TREATMENT OUTCOME;

EID: 84865341114     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.693473     Document Type: Review

References (98)

1. Rowland GF, O'Neill GJ, Davies DA. Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage. Nature 1975;255:487-8
2. Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 2004;48:251-7 (Pubitemid 43932934)
3. Getts DR, Getts MT, McCarthy DP, et al. Have we overestimated the benefit of human(ized) antibodies? MAbs 2010;2:682-94
4. Beerli RR, Rader C. Mining human antibody repertoires. MAbs 2010;2:365-78
5. Andersen JT, Sandlie I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab Pharmacokinet 2009;24:318-32
6. Kuo TT, Baker K, Yoshida M, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010;30:777-89
7. Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006;56:226-43 (Pubitemid 44175051)
8. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci 2008;29:57-61
9. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60:1421-34
10. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009;8:2861-71
11. Zahnd C, Kawe M, Stumpp MT, et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 2010;70:1595-605
12. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107
13. Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins (Basel) 2011;3:848-83
14. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21:778-84 (Pubitemid 36791396)
15. Doronina SO, Mendelsohn BA, Bovee TD, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114-24 (Pubitemid 43157592)
16. Widdison WC, Wilhelm SD, Cavanagh EE, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-408 (Pubitemid 44036683)
17. Beusker PH, Coumans RGE, Elgersma RC, et al. Novel conjugates of CC-1065 analogs and bifunctional linkers. WO2011133039A2; 2011
18. Beusker PH, Spijker HJ, Joosten JAF, et al. Preparation of substituted CC-1065 analogs and their conjugates for treating tumors. WO2009017394A1; 2009
19. Gangwar S, Zhang Q. Preparation of CC-1065 analogs as potent cytotoxins and their intermediates. WO2007051081A1; 2007
20. Hartley JA. The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs 2011;20:733-44
21. Metz S, Haas AK, Daub K, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci USA 2011;108:8194-9
22. Sato H. Enzymatic procedure for site-specific pegylation of proteins. Adv Drug Deliv Rev 2002;54:487-504 (Pubitemid 34615545)
23. Hussain AF, Kampmeier F, von Felbert V, et al. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Bioconjug Chem 2011;22:2487-95
24. Wakankar AA, Feeney MB, Rivera J, et al. Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. Bioconjug Chem 2010;21:1588-95
25. White CA, Weaver RL, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 2001;52:125-45 (Pubitemid 32197306)
26. Al Ejeh F, Darby JM, Thierry B, Brown MP. A simplified suite of methods to evaluate chelator conjugation of antibodies: effects on hydrodynamic radius and biodistribution. Nucl Med Biol 2009;36:395-402
27. Shin IS, Lee SM, Kim HS, et al. Effect of chelator conjugation level and injection dose on tumor and organ uptake of 111In-labeled MORAb-009, an anti-mesothelin antibody. Nucl Med Biol 2011;38:1119-27
28. Burris HA. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer. Expert Opin Biol Ther 2011;11:807-19
29. LoRusso PM, Weiss D, Guardino E, et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011;17:6437-47
30. Wang L, Amphlett G, Blattler WA, et al. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005;14:2436-46 (Pubitemid 41252812)
31. Kinstler O, Molineux G, Treuheit M, et al. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2002;54:477-85 (Pubitemid 34615544)
32. Manjappa AS, Chaudhari KR, Venkataraju MP, et al. Antibody derivatization and conjugation strategies: application in preparation of stealth immunoliposome to target chemotherapeutics to tumor. J Control Release 2011;150:2-22
33. Sun MM, Beam KS, Cerveny CG, et al. Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 2005;16:1282-90 (Pubitemid 41368132)
34. Hofer T, Thomas JD, Burke TR Jr, Rader C. An engineered selenocysteine defines a unique class of antibody derivatives. Proc Natl Acad Sci USA 2008;105:12451-6
35. Junutula JR, Raab H, Clark S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008;26:925-32
36. Lyons A, King DJ, Owens RJ, et al. Site-specific attachment to recombinant antibodies via introduced surface cysteine residues. Protein Eng 1990;3:703-8 (Pubitemid 20284843)
37. McDonagh CF, Kim KM, Turcott E, et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index. Mol Cancer Ther 2008;7:2913-23
38. Stimmel JB, Merrill BM, Kuyper LF, et al. Site-specific conjugation on serine right-arrow cysteine variant monoclonal antibodies. J Biol Chem 2000;275:30445-50
39. Voynov V, Chennamsetty N, Kayser V, et al. Design and application of antibody cysteine variants. Bioconjug Chem 2010;21:385-92
40. Baker TS, Humphreys DP, Lawson ADG. Altered human IgG antibodies and conjugates for disease diagnosis and therapy. WO2008038024A1; 2008
41. Dimasi N, Gao C, Wu H. CH1 domain cysteine-substituted antibodies for site-specific conjugation and for diagnosis and treatment of inflammation, autoimmune disease, cancer or infection. WO2009092011A1; 2009
42. Liu H, Chumsae C, Gaza-Bulseco G, et al. Ranking the Susceptibility of Disulfide Bonds in Human IgG1 Antibodies by Reduction, Differential Alkylation, and LCMS Analysis. Anal Chem 2010;82:5219-26
43. Gillies SD, Wesolowski JS. Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities. Hum Antibodies Hybridomas 1990;1:47-54 (Pubitemid 20320603)
44. Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004;10:7063-70 (Pubitemid 39383058)
45. McDonagh CF, Turcott E, Westendorf L, et al. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 2006;19:299-307 (Pubitemid 43999640)
46. Junutula JR, Bhakta S, Raab H, et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs. J Immunol Methods 2008;332:41-52
47. Humphreys DP, Heywood SP, Henry A, et al. Alternative antibody Fab fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering. Protein Eng Des Sel 2007;20:227-34 (Pubitemid 351321304)
48. Hamel PA, Klein MH, Dorrington KJ. The role of the VL-and VH-segments in the preferential reassociation of immunoglobulin subunits. Mol Immunol 1986;23:503-10 (Pubitemid 16113212)
49. Dillon TM, Ricci MS, Vezina C, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008;283:16206-15
50. Taylor FR, Prentice HL, Garber EA, et al. Suppression of sodium dodecyl sulfate-polyacrylamide gel electrophoresis sample preparation artifacts for analysis of IgG4 half-antibody. Anal Biochem 2006;353:204-8 (Pubitemid 43775437)
51. Balan S, Choi JW, Godwin A, et al. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge. Bioconjug Chem 2007;18:61-76 (Pubitemid 46145995)
52. Mylotarg package insert: W10477C009 ET01. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2006/021174s020lbl.pdf [Last accessed 3 March 2012]
53. DiJoseph JF, Goad ME, Dougher MM, et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2004;10:8620-9 (Pubitemid 40053430)
54. Full Prescribing Information for Adcetris. Seattle Genetics, Inc. Available from: http://www.adcetris.com/-pdf/Final-Adcetris-USPI-Jan12-2012.pdf [Last accessed 3 March 2012]
55. CDER Application No 125388Orig1s000 Chemistry Review(s). Center for Drug Evaluation and Research. Available from: http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/125388Orig1s000ChemR.pdf [Last accessed 3 March 2012]
56. Shen BQ, Xu K, Liu L, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012;30:184-9
57. Hutchins BM, Kazane SA, Staflin K, et al. Selective formation of covalent protein heterodimers with an unnatural amino acid. Chem Biol 2011;18:299-303
58. Kellogg BA, Garrett L, Kovtun Y, et al. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 2011;22:717-27
59. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2010;21:5-13
60. Derwin D, Passore D, Sung J, et al. Activation of antibody drug conjugate MDX-1203 by Human Carboxylesterase 2. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract nr 2575
61. Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 2011;20:1131-49
62. Kovtun YV, Audette CA, Mayo MF, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 2010;70:2528-37
63. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006;66:4426-33
64. Polson AG, Ho WY, Ramakrishnan V. Investigational antibody-drug conjugates for hematological malignancies. Expert Opin Investig Drugs 2011;20:75-85
65. Teicher BA, Chari RV. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 2011;17:6389-97
66. Teicher BA. Antibody-drug conjugate targets. Curr Cancer Drug Targets 2009;9:982-1004
67. Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. MAbs 2009;1:443-52
68. Breccia M, Lo-Coco F. Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opin Biol Ther 2011;11:225-34
69. Hutter ML, Schlenk RF. Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia. Expert Opin Biol Ther 2011;11:1369-80
70. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011;17:6417-27
71. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-6 (Pubitemid 32708610)
72. Pfizer prepares for voluntary withdrawal of U.S. New drug application and for discontinuation of commercial availability Of Mylotarg® . Pfizer, Inc. Available from: http://www.pfizer.com/files/news/press-releases/2010/mylotarg- discontinuation-062110.pdf [Last accessed 3 March 2012]
73. Pfizer prepares for voluntary withdrawal of U.S. New drug application and for discontinuation of commercial availability of mylotarg for relapsed acute myeloid leukemia. Pfizer, Inc. Available from: http://www.pfizer.com/files/ products/mylotarg-hcp-letter.pdf [Last accessed 3 March 2012]
74. S0106 Cytarabine and Daunorubicin with or without Gemtuzumab Ozogamicin Followed by high-dose cytarabine followed by either Gemtuzumab Ozogamicin or No additional therapy in treating patients with previously untreated De Novo acute myeloid leukemia. ClinicalTrials.gov Available from: http://www.clinicaltrials. gov/ct2/show/NCT00085709?term=S0106&rank=1 [Last accessed 3 March 2012]
75. Pautas C, Terre C, Raffoux E, Dombret H. Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) improve event-free and overall survival in newly-diagnosed De Novo AML patients aged 50-70 years old: a prospective randomized phase 3 trial from the Acute Leukemia French Association (ALFA). 2011
76. ASH: Gemtuzumab\-A Potential New Use for an Old Drug in AML. cancernetwork.com. Available from: http://www.cancernetwork. com/conference-reports/ash2011/content/article/10165/2005126 [Last accessed 3 March 2012]
77. Pfizer's failed blood cancer drug shows benefits in study of new patients. BLOOMBERG L.P. Available from: http://www.bloomberg.com/news/2011-12- 10/pfizer-s-failed-blood-cancer-drug-shows-benefits-in-study-of-new-patients. html [Last accessed 3 March 2012]
78. Genentech Provides Update on FDA Application for T-DM1. Genentech, Inc. Available from: http://www.gene.com/gene/news/press-releases/display.do?method= detail&id=12947 [Last accessed 3 March 2012]
79. Genentech's Investigational Medicine T-DM1 Showed Improvement in Progression-Free Survival Compared to Standard of Care in HER2-Positive Metastatic Breast Cancer. Genentech, Inc. Available from: http://www.gene. com/gene/news/press-releases/display.do? method=detail&id=13607 [Last accessed 3 March 2012]
80. Roche's trastuzumab emtansine (T-DM1) showed positive Phase III results in HER2-positive metastatic breast cancer. F. Hoffmann-La Roche Ltd. Available from: http://www.roche.com/media/media-releases/med-cor-2012-03-30.htm [Last accessed 2 April 2012]
81. An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA). ClinicalTrials.gov Available from: http://www.clinicaltrials. gov/ct2/show/NCT00829166 [Last accessed 3 March 2012]
82. Ansell SM. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells. Expert Opin Investig Drugs 2011;20:99-105
83. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN-35). Clin Cancer Res 2011;17:6428-36
84. Drug Approval Package: ADCETRIS (brentuximab vedotin). U.S. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/ nda/2011/125399-adcetris-toc.cfm [Last accessed 3 March 2012]
85. Briefing Information for the July 14, 2011 Meeting of the Oncologic Drugs Advisory Committee. U.S. Food and Drug Administration. Available from: http://www.fda.gov/advisorycommittees/committeesmeetingmaterials/drugs/ oncologicdrugsadvisorycommittee/ucm262590.htm [Last accessed 3 March 2012]
86. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010;1:314-22
87. Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010;2:256-65
88. Wong BY, Dang NH. Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol Ther 2010;10:1251-8
89. A Study of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy. ClinicalTrials.gov Available from: http://www. clinicaltrials.gov/ct2/show/NCT01232556 [Last accessed 3 March 2012]
90. Genentech's Research and Early Development pipeline has over 30 new molecular entities in clinical development. Genentech, Inc. Available from: http://www.gene.com/gene/gred/science/pipeline/[Last accessed 3 March 2012]
91. Antibody-drug Conjugate Technology Collaborations. Seattle Genetics, Inc. Available from: http://www.seagen.com/collaborations-ADC.shtml [Last accessed 3 March 2012]
92. Immunogen, Inc.: Securities and Exchange Commission form 8-K: Nov 29, 2011. Available from: http://www.faqs.org/sec-filings/111129/IMMUNOGEN-INC-8-K/ [Last accessed 3 March 2012]
93. Morphosys 3rd Interim Report Oct 2011. Available from: http://www.morphosys.com/sites/default/files/111028-MOR-Q3-2011-e.pdf [Last accessed 3 March 2012]
94. Wilex AG announces acquisition of Heidelberg Pharma AG. WILEX AG. Available from: http://www.wilex.de/pdf/Adhoc/2010/20101103-AH-WILEX- HDPAcquisition-eng.pdf [Last accessed 3 March 2012]
95. Synthon acquires Syntarga and its Antibody-Drug Conjugate Technology. Synthon BV. Available from: http://www.synthon.com/en/nieuwsarchief/synthon- acquires-syntarga-and-its-antibody-drug-conjugate-technology.aspx [Last accessed 3 March 2012]
96. Spirogen Ltd. announces a research collaboration and license agreement with Genentech for the discovery and development of antibody drug conjugates. Available from: http://www.spirogen.com/news/latest.php [Last accessed 3 March 2012]
97. Seattle Genetics Demonstrates Continued Leadership in Antibody-Drug Conjugates at AACR. Seattle Genetics, Inc. Available from: http://www. businesswire.com/news/home/20120403006655/en/Seattle-Genetics-Demonstrates- Continued-Leadership-Antibody-Drug-Conjugates [Last accessed 23 April 2012]
98. Seattle Genetics and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer. Available from: http://www.oxbt.co.uk/pdf/ OBT-SGEN-20110913.pdf